Virpax Pharmaceuticals Inc.: Funding, Investors & Team (Sep 2026)
Virpax® is focused on developing and commercializing non-addictive pain products. Virpax has global rights to an intranasal New Chemical Entity (NCE) that deliverers enkephalin to the brain utilizing a Nanoparticle-Molecular Envelope Technology (MET) to manage chronic pain, cancer pain, and post-traumatic stress disorder (Post-Traumatic Stress Disorder (PTSD). “Enkephalins are naturally occurring analgesics in our body that bind predominantly to the delta-receptor. Delta opioid receptors have a built-in mechanism for pain relief. They can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inflammatory pain with fewer side effects” (Journal of Controlled Release). Virpax has the rights to two 505b2 product candidates; an "NSAID" Topical Spray Film Delivery Technology for localized musculoskeletal pain, and an injectable “local anesthetic” Liposomal Hydro-Gel Technology for postoperative pain management. MMS019, is an intranasal Nanoparticle-MET liquid dispersion being developed to help prevent viral spread caused by influenza and SARS-CoV-2. Future product candidates will include treatments for neurological disorders.
Virpax Pharmaceuticals Inc. has raised $58.0M across 2 funding rounds on record, the most recent a Post-IPO Equity of $40.0M announced in Sep 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Virpax Pharmaceuticals Inc. Company Profile and Key Stats
Latest funding round on record: Sep 2021.
Virpax Pharmaceuticals Inc. Funding Rounds
Virpax Pharmaceuticals Inc. raised $18.0M in a Series C announced in Feb 2021.
7 months later, a Post-IPO Equity of $40.0M was announced in Sep 2021.
Virpax Pharmaceuticals Inc. Founders and Leadership Team
Contact details for the Virpax Pharmaceuticals Inc. team: 1 of 1 has an email address on file.
Start 14-day free trial →Virpax Pharmaceuticals Inc. Funding Compared to Other Biotechnology Startups
Virpax Pharmaceuticals Inc.'s latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Virpax Pharmaceuticals Inc. in Biotechnology and Berwyn
Companies Similar to Virpax Pharmaceuticals Inc.
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Virpax Pharmaceuticals Inc. Funding FAQs
What does Virpax Pharmaceuticals Inc. do?
Virpax® is focused on developing and commercializing non-addictive pain products. Virpax has global rights to an intranasal New Chemical Entity (NCE) that deliverers enkephalin to the brain utilizing a Nanoparticle-Molecular Envelope Technology (MET) to manage chronic pain, cancer pain, and post-traumatic stress disorder (Post-Traumatic Stress Disorder (PTSD). “Enkephalins are naturally occurring analgesics in our body that bind predominantly to the delta-receptor. Delta opioid receptors have a built-in mechanism for pain relief. They can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inflammatory pain with fewer side effects” (Journal of Controlled Release). Virpax has the rights to two 505b2 product candidates; an "NSAID" Topical Spray Film Delivery Technology for localized musculoskeletal pain, and an injectable “local anesthetic” Liposomal Hydro-Gel Technology for postoperative pain management. MMS019, is an intranasal Nanoparticle-MET liquid dispersion being developed to help prevent viral spread caused by influenza and SARS-CoV-2. Future product candidates will include treatments for neurological disorders.
How much funding has Virpax Pharmaceuticals Inc. raised?
Virpax Pharmaceuticals Inc. has raised $58.0M across 2 rounds on record. The most recent is a Post-IPO Equity of $40.0M announced in Sep 2021.
When did Virpax Pharmaceuticals Inc. last raise funding?
Virpax Pharmaceuticals Inc.'s most recent funding round on record is a Post-IPO Equity of $40.0M, announced in Sep 2021.
Who is the CEO of Virpax Pharmaceuticals Inc.?
Anthony Mack is listed as CEO at Virpax Pharmaceuticals Inc..
Where is Virpax Pharmaceuticals Inc. headquartered?
Virpax Pharmaceuticals Inc. is based in Berwyn, Pennsylvania, United States.
How many employees does Virpax Pharmaceuticals Inc. have?
Virpax Pharmaceuticals Inc. is in the 1-10 employee band.
How does Virpax Pharmaceuticals Inc.'s funding compare to other Biotechnology startups?
Virpax Pharmaceuticals Inc.'s latest round of $40.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Virpax Pharmaceuticals Inc. Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Virpax Pharmaceuticals Inc. is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.